ArticlemedRxiv : the preprint server for health sciences2026
Disorder-specific and shared genetic architecture underlying schizophrenia and bipolar disorder.
Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Schizophrenia (SCZ) and bipolar disorder (BIP) share substantial common-variant liability but differ in cognitive, comorbidity, and treatment response. Here we decomposed these disorders into schizophrenia-predominant, bipolar-predominant, and shared psychosis dimensions to test whether these components show distinct pleiotropic and biological profiles than the original disorder. Using the largest available SCZ and BIP GWAS, we applied bidirectional mtCOJO and Genomic SEM to derive SCZcondBIP, BIPcondSCZ, and PSY-shared and validated them using inter-component genetic correlations, FinnGen psychiatric endpoints, and Genomic SEM latent factors. We then characterized each component across cognitive, cardiometabolic, and immune traits, followed by genomic risk-locus discovery, pathway analysis, developmental expression profiling, and drug-target enrichment. The three components showed marked divergence. SCZcondBIP was negatively correlated with cognition, education, metabolic syndrome, C-reactive protein, and neutrophil percentage, whereas BIPcondSCZ showed the opposite cognitive profile and shifted toward positive cardiometabolic and immune correlations. PSY-shared remained positively correlated with education and negatively correlated with cognitive task performance, immune and metabolic traits. We identified 248 consensus genomic risk loci, including 81 not detected in the input disorder GWAS. Biologically, PSY-shared was enriched for synaptic signalling, ion-channel, and neurodevelopmental pathways; SCZcondBIP primarily implicated synaptic-signalling and cellular-homeostasis pathways; and BIPcondSCZ showed weaker but distinct enrichment for synaptic-vesicular biology. Drug-target enrichment further separated the components, with strong antipsychotic enrichment for PSY-shared and distinct non-antipsychotic signals for the conditional factors. These findings show that SCZ and BIP genetic risk is best understood as biologically distinguishable shared and disorder-predominant dimensions that differentially map onto cognitive, cardiometabolic, immune, and molecular architecture. These findings provide a framework for evaluating whether component-specific polygenic scores improve stratification of cognitive, cardiometabolic, and inflammatory heterogeneity across severe psychiatric illness.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.